News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Incorporated First Quarter 2006 Financial Results Conference Call Transcript
Moderator: Jody Cain May 5, 2006, 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2006 First Quarter Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we’ll hold a Q&A session.
View HTML
Toggle Summary AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
NeuGene Antisense Efficacy Against Influenza Strains Reported at the International Conference on Antiviral Research   PORTLAND, Ore.--(BUSINESS WIRE)--May 9, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented positive preclinical data, resulting from preclinical experiments targeting
View HTML
Toggle Summary AVI BioPharma Announces First Quarter Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--May 5, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three months ended March 31, 2006. For the first quarter of 2006, AVI reported a net loss of $9.1 million, or $0.18 per share, compared with a net loss of $5.5 million, or $0.13
View HTML
Toggle Summary AVI BioPharma Announces 2006 First Quarter Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--April 28, 2006--AVI BioPharma Inc. (Nasdaq:AVII) today announced that the company will hold a conference call to discuss its 2006 first quarter financial results on Friday, May 5, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma to Present at UBS Global Specialty Pharmaceuticals Conference
PORTLAND, Ore., Apr 21, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, April 24, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Specialty Pharmaceuticals Conference to be
View HTML
Toggle Summary AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR   PORTLAND, Ore.--(BUSINESS WIRE)--April 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today issued an update on the status of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection.
View HTML
Toggle Summary AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NEUGENE Antisense Therapeutic
PORTLAND, Ore.--(BUSINESS WIRE)--March 30, 2006-- Preclinical Results by Four Independent Laboratories Summarized and Presented at Keystone Symposia: Advances in Influenza Research AVI BioPharma, Inc. (Nasdaq:AVII), today announced the presentation of research results titled "Inhibition of Multiple
View HTML
Toggle Summary AVI BioPharma and Cook Group Enter Into License Agreement to Develop NEUGENE Drugs for Vascular Diseases
PORTLAND, Ore.--(BUSINESS WIRE)--March 13, 2006-- Cook to Fund All Clinical Development of Three Products for Cardiovascular Restenosis and Develop Products for Peripheral Vascular Diseases AVI BioPharma, Inc. (Nasdaq: AVII), today announced that it has entered into agreements with Cook Group Inc.
View HTML
Toggle Summary AVI BioPharma Incorporated 2005 Fourth Quarter and Year–End Financial Results Conference Call Transcript
Moderator: Denis Burger March 8, 2006 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2005 Fourth Quarter and Year–End Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we’ll hold a Q&A session.
View HTML
Toggle Summary AVI BioPharma Announces 2005 Fourth Quarter and Full Year Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--March 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and 12 months ended December 31, 2005. For the fourth quarter of 2005, AVI reported a net loss of $4.6 million, or $0.10 per share, compared with a net loss of $5.0
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.